# A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)

> **NCT02184611** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 308 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Umeclidinium bromide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02184611
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-09
- **Primary completion:** 2017-11-08
- **Final completion:** 2017-11-08
- **Target enrollment:** 308 (ACTUAL)
- **Last updated:** 2020-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02184611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02184611, "A 24 Week Efficacy Study of Inhaled Umeclidinium (UMEC) in Patients of Chronic Obstructive Pulmonary Disease (COPD) Using a Novel Dry Powder Inhaler (NDPI)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02184611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*